Nucleic Acids Research, 1995, Vol. 23, No. 13 2450-2456
© 1995
CHEMISTRY |
Use of oligonucletides to define the site of interstand cross-links induced by Adriamycin
School of Biochemistry, La Trobe University Bundoora, Victoria 3083, Australia
*To whom corespondence should be addressed
Received April 1, 1995. Accepted May 24, 1995.
It has been known for several years that Adriamycin forms adducts and interstrand cross-links when reacted for long periods of time with bacterial and mammalian DNA in vitro, with the cross-link being restricted to 2 bp elements containing GpC quences.The self-complementary 20mer deoxyoligonucleotide TA4T4GCA4T4A has been used in this study as a model of the apparent G-G cross-linking site at GpC sequences. The rate of formation of cross-links, as well as the dependence on both Adriamycin and Fe(lll) concentration, were similar with this llgonucleotlde as compared with calf thymus DNA. The cross-linking was demonstrated on both denaturing and non-denaturing sequencing gels. The half-life of the G-G cross-link was 40 h, consistent with that implied with high molecular weight, heterogeneous sequence DNA. Exonuclease III digests of adducts formed with 20mer eoxyoligonucleotides containing single, central G-G, G-I and l-l otential cross-links revealed that a guanine residue is required at both ends of the cross-link. No cross-linking was observed with a similar oligonucleotide containing only a single central (GC) bp.
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
K. E. Coldwell, S. M. Cutts, T. J. Ognibene, P. T. Henderson, and D. R. Phillips Detection of Adriamycin-DNA adducts by accelerator mass spectrometry at clinically relevant Adriamycin concentrations Nucleic Acids Res., July 16, 2008; (2008) gkn439v1. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Cutts, L. P. Swift, A. Rephaeli, A. Nudelman, and D. R. Phillips Sequence Specificity of Adriamycin-DNA Adducts in Human Tumor Cells Mol. Cancer Ther., July 1, 2003; 2(7): 661 - 670. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. P. Swift, S. M. Cutts, A. Rephaeli, A. Nudelman, and D. R. Phillips Activation of Adriamycin by the pH-dependent Formaldehyde-releasing Prodrug Hexamethylenetetramine Mol. Cancer Ther., February 1, 2002; 2(2): 189 - 198. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Cutts, A. Rephaeli, A. Nudelman, I. Hmelnitsky, and D. R. Phillips Molecular Basis for the Synergistic Interaction of Adriamycin with the Formaldehyde-releasing Prodrug Pivaloyloxymethyl Butyrate (AN-9) Cancer Res., November 1, 2001; 61(22): 8194 - 8202. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Zeman, D. R. Phillips, and D. M. Crothers Characterization of covalent Adriamycin-DNA adducts PNAS, September 29, 1998; 95(20): 11561 - 11565. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Cutts, P. G. Parsons, R. A. Sturm, and D. R. Phillips Adriamycin-induced DNA Adducts Inhibit the DNA Interactions of Transcription Factors and RNA Polymerase J. Biol. Chem., March 8, 1996; 271(10): 5422 - 5429. [Abstract] [Full Text] [PDF] |
||||




